Management of Peyronie's disease after collagenase (Xiaflex:®).
Although the prevalence of Peyronie's disease (PD) is reported to be 3-9% in men, the true prevalence is likely higher due to under-reporting. Many treatment modalities have been described for PD with varying degrees of success. In this article, we review and summarize the current literature pertaining to all pharmacotherapies (oral, intralesional, iontophoresis, and topical) and minimally invasive treatments available for PD (vacuum, traction device, shock wave therapy, and radiation treatment). Additionally, we discuss emerging therapies for PD that are still in pre-clinical development, including stem cell therapy.
Amjad
A
Alwaal
Ahmed Aly
AA
Hussein
Uwais B
UB
Zaid
University of California, San Francisco, Box 0738, 1600 Divisadero St., MZ Bldg A, Room A609, San Francisco, CA 94143, USA. amjadwal@yahoo.com.
Tom F
TF
Lue
D000818:Animals; D004359:Drug Therapy, Combination / Q000379:methods*; D006801:Humans; D008297:Male; D003012:Microbial Collagenase / Q000627:therapeutic use; D010411:Penile Induration / Q000188:drug therapy* / Q000453:epidemiology / Q000534:rehabilitation*; D015917:Penile Prosthesis; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
D003012:Microbial Collagenase